Eli Lilly (LLY) Liabilities from Discontinued Operations (2018)
Eli Lilly (LLY) posted Liabilities from Discontinued Operations of 2742300000.0 for Q4 2018.
Eli Lilly (LLY) Liabilities from Discontinued Operations (2018) Analysis & Trends
Eli Lilly (LLY) has reported Liabilities from Discontinued Operations for 1 consecutive years, with 2742300000.0 the latest figure, recorded in Q4 2018.
- Liabilities from Discontinued Operations for Q4 2018 came in at 2742300000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was 2742300000.0 (changed N/A YoY), and the FY2018 annual result was 2742300000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was 2742300000.0 for Q4 2018 at Eli Lilly.
- Over five years, Liabilities from Discontinued Operations peaked at 2742300000.0 in Q4 2018 and troughed at 2742300000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 2.74 Bn |
| Dec 31, 2018 | 2.74 Bn |